Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL880976 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2NPSR1CYP2C9CYP2C19PSEN1 | |
| SCHEMBL880979 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2NPSR1CYP2C9CYP2C19PSEN1 | |
| SCHEMBL1901754 | 0.72 | PSEN1 (0.45) | SMN1; SMN2NPSR1CYP2C9CYP2C19PSEN1 | |
| SCHEMBL11719403 | 0.68 | CYP2C9 (0.42) | SMN1; SMN2NPSR1CYP2C9CYP2C19PSEN1 | |
| SCHEMBL11683106 | 0.67 | PSEN1 (0.52) | SMN1; SMN2NPSR1CYP2C9CYP2C19PSEN1 | |
| SCHEMBL19909860 | 0.67 | CYP2C9 (0.37) | SMN1; SMN2NPSR1CYP2C9CYP2C19PSEN1 | |
| SCHEMBL5052551 | 0.67 | CYP2C9 (0.38) | SMN1; SMN2NPSR1CYP2C9CYP2C19MTNR1A | |
| SCHEMBL13807076 | 0.67 | CYP2C9 (0.38) | SMN1; SMN2NPSR1CYP2C9CYP2C19MTNR1A | |
| SCHEMBL13805721 | 0.67 | CYP2C9 (0.38) | SMN1; SMN2NPSR1CYP2C9CYP2C19MTNR1A | |
| SCHEMBL15180280 | 0.66 | SMN1; SMN2 (0.38) | SMN1; SMN2NPSR1CYP2C9CYP2C19PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614049-B1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Nabriva Therapeutics GmbH (AT) | 2018-02-28 | — | — | EP | disclosed |
| EP-2614049-B1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Nabriva Therapeutics GmbH (AT) | 2018-02-28 | — | — | EP | disclosed |
| US-9278920-B2 | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2016-03-08 | — | — | US | disclosed |
| US-9278920-B2 | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2016-03-08 | — | — | US | disclosed |
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2013-10-17 | — | — | US | disclosed |
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2013-10-17 | — | — | US | disclosed |
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2013-10-17 | — | — | US | disclosed |
| WO-2012031307-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Q6ZSR9, CUTA, MC4R | SMN1; SMN2 3027/4885NPSR1 2428/4885CYP2C9 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.